U.S. markets closed
  • S&P 500

    4,134.94
    -28.32 (-0.68%)
     
  • Dow 30

    33,821.30
    -256.33 (-0.75%)
     
  • Nasdaq

    13,786.27
    -128.50 (-0.92%)
     
  • Russell 2000

    2,188.21
    -43.79 (-1.96%)
     
  • Crude Oil

    62.61
    -0.77 (-1.21%)
     
  • Gold

    1,779.20
    +8.60 (+0.49%)
     
  • Silver

    25.88
    +0.04 (+0.15%)
     
  • EUR/USD

    1.2037
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • GBP/USD

    1.3941
    -0.0043 (-0.31%)
     
  • USD/JPY

    108.0690
    -0.0810 (-0.07%)
     
  • BTC-USD

    56,492.87
    +432.75 (+0.77%)
     
  • CMC Crypto 200

    1,280.13
    +45.72 (+3.70%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

Cathie Wood Weighs In On Invitae Corp

  • Oops!
    Something went wrong.
    Please try again later.
Craig Jones
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Speaking on CNBC's "Closing Bell," Ark VInestment Management CEO Cathie Wood said Invitae Corp (NYSE: NVTA), in the molecular diagnostics space, is probably one of the most important companies in the genomic revolution and it's getting hammered.

Historically, Wood said, it has had small cash cushions although it rectified that with offerings, which is great. She added that the company is investing aggressively to be the leader in the molecular diagnostic and testing space.

See Also: Cathie Wood Shares Thoughts On Nano Dimension

Wood said the disconnect for many people here is when they think about lab tests, they think of Laboratory Corp. of America Holdings (NYSE: LH) and Quest Diagnostics Inc (NYSE: DGX), which are effectively very mature companies, commoditized, value stocks. She expects the new lab tests to be supported by artificial intelligence, big data and supercomputing power amid a move towards personalized medicine, which is going to give just a few companies the lion share of the market.

These companies are going to have the most data, the highest quality data and the best AI expertise, Wood said.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.